In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor
- 31 October 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 27 (2) , 192-202
Abstract
Accumulating evidence supports a role for κ−opioid receptor antagonists in the treatment of mood disorders. Standard κ-antagonists have an unusual pharmacodynamic action, with a single injection blocking receptor signaling for several weeks. Here, we have characterized the κ-selective properties of two ligands, 5’-(2-aminomethyl) naltrindole (5’-AMN) and N-((Naltrindol-5-yl) methyl) pentanimidamide (5’-MABN), to identify whether modifications of the naltrindole side chain produces short-acting κ-antagonists. Opioid receptor binding affinity and activity were assessed using [3H]-diprenorphine binding, guanosine-5’-O-(3-[35S]-thio) triphosphate ([35S]-GTPγS) binding and isolated guinea-pig ileum. Pharmacodynamic profiles of 5’-AMN and 5’-MABN (1–10 mg/kg) were investigated using the tail-withdrawal assay and diuresis. Efficacy was also determined in depression- and anxiety-related behavioral paradigms in CD-1 mice. Both 5’-AMN and 5’-MABN had high affinity for κ−receptors ( Ki1.36±0.98 and 0.27±0.08, respectively) and were revealed as potent κ-antagonists ( pA27.43 and 8.18, respectively) and μ-receptor antagonists ( pA27.62 and 7.85, respectively) in the ileum. Contrary to our hypothesis, in vivo, 5’-AMN and 5’-MABN displayed long-lasting antagonist effects in mice, reducing the antinociceptive actions of U50,488 (10 mg/kg) at 28 and 21 days post-injection, respectively. Interestingly, while 5’-AMN and 5’-MABN were not κ-selective, both compounds did show significant antidepressant- and anxiolytic-like effects at 7–14 days post-injection in mice.Keywords
This publication has 67 references indexed in Scilit:
- Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signalingProceedings of the National Academy of Sciences, 2010
- Kinase cascades and ligand-directed signaling at the kappa opioid receptorPsychopharmacology, 2010
- Dynorphin, stress, and depressionBrain Research, 2010
- The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviorsBrain Research, 2010
- Kappa-opioid ligands in the study and treatment of mood disordersPharmacology & Therapeutics, 2009
- 30 years of dynorphins — New insights on their functions in neuropsychiatric diseasesPharmacology & Therapeutics, 2009
- Mixed κ/μ Opioid Receptor Agonists: The 6β-NaltrexaminesJournal of Medicinal Chemistry, 2009
- κ-Opioid System Regulates the Long-Lasting Behavioral Adaptations Induced by Early-Life Exposure to MethylphenidateNeuropsychopharmacology, 2008
- Prodynorphin-Derived Peptides Are Critical Modulators of Anxiety and Regulate Neurochemistry and CorticosteroneNeuropsychopharmacology, 2008
- Central κ-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studiesEuropean Journal of Pharmacology, 2007